4//SEC Filing
LYNCH DANIEL 4
Accession 0001104659-25-012364
CIK 0001773427other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 7:59 PM ET
Size
8.8 KB
Accession
0001104659-25-012364
Insider Transaction Report
Form 4
LYNCH DANIEL
Director
Transactions
- Sale
Common Stock
2025-02-10$53.23/sh−69,766$3,713,553→ 236,178 total - Sale
Common Stock
2025-02-10$55.51/sh−65,600$3,641,751→ 130,944 total - Sale
Common Stock
2025-02-10$54.88/sh−39,634$2,175,047→ 196,544 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on May 3, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.28 to $55.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.40 to $55.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Documents
Issuer
SpringWorks Therapeutics, Inc.
CIK 0001773427
Entity typeother
Related Parties
1- filerCIK 0001177082
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 7:59 PM ET
- Size
- 8.8 KB